Log in to search using one of your social media accounts:

 

Intra-operative use of one-step nucleic acid amplification (OSNA) for detection of the tumor load of sentinel lymph nodes in breast cancer patients.
CONCLUSION: We found OSNA to be very helpful for the intra-operative determination of the tumor load of a SLN as a basis for decision-making concerning further surgical axillary intervention. OSNA allows precise differentiation of micro- from macrometastasis, and the CK19 copy number predicts the probability of tumor load in other axillary lymph nodes and might help to find adequate adjuvant treatment options. This objective method is well suitable for everyday use and may reduce the pathologic workload and the risk of secondary operative interventions with all associated costs and stress for the patients. PMID: 23907...
Source: Clinical Breast Cancer - August 2, 2013 Category: Cancer & Oncology Authors: Heilmann T, Mathiak M, Hofmann J, Mundhenke C, van Mackelenbergh M, Alkatout I, Wenners A, Eckmann-Scholz C, Schem C Tags: J Cancer Res Clin Oncol Source Type: research

TIS21(/BTG2) inhibits invadopodia formation by downregulating reactive oxygen species level in MDA-MB-231 cells.
CONCLUSIONS: This is the first report to provide insight into invasion signals regulated by tumor suppressor, TIS21(/BTG2/Pc3) gene, in the intractable breast cancer cells. PMID: 23907596 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - August 2, 2013 Category: Cancer & Oncology Authors: Choi JA, Lim IK Tags: J Cancer Res Clin Oncol Source Type: research

Steroid receptor RNA activator protein (SRAP) expression as a prognostic factor in ER+ human breast tumors.
Abstract BACKGROUND: The steroid receptor RNA activator protein (SRAP) is a newly described protein modulating the activity of multiple transcription factors including the estrogen receptor (ER). We have recently reported the immunodetection by Western blot of multiple SRAP peptides in breast tissue. High expression of these peptides, assessed by tissue micro-array (TMA) analysis, was associated with poor prognosis in patients whose primary tumors were ER positive (ER+). In such studies, it is recognized that intensity as well as specificity of the signal detected directly depends upon the antibody used as well as...
Source: Clinical Breast Cancer - August 2, 2013 Category: Cancer & Oncology Authors: Yan Y, Penner CC, Skliris GP, Cooper C, Nugent Z, Blanchard A, Hamedani MK, Wang X, Myal Y, Murphy LC, Leygue E Tags: J Cancer Res Clin Oncol Source Type: research

A Non-invasive Modality: The US Virtual Touch Tissue Quantification (VTTQ) for Evaluation of Breast Cancer.
Abstract OBJECTIVE: We evaluated the biologic features of breast tissues using a newly developed non-invasive diagnostic system, named virtual touch tissue quantification. METHODS: A total of 180 patients including 115 invasive ductal carcinoma, 30 ductal carcinoma in situ, 4 mucinous carcinoma, 7 invasive lobular carcinoma, 8 fibroadenoma, 12 fibrocystic change and 4 intraductal papilloma were studied at Nahanishi Clinic, Okinawa. We first compared the results of virtual touch tissue quantification according to each histologic subtype and determined the optimal cutoff values for virtual touch tissue quantifi...
Source: Clinical Breast Cancer - August 2, 2013 Category: Cancer & Oncology Authors: Tamaki K, Tamaki N, Kamada Y, Uehara K, Miyashita M, Ishida T, Sasano H Tags: Jpn J Clin Oncol Source Type: research

Circulating plasma DNA and DNA integrity in breast cancer patients undergoing neoadjuvant chemotherapy.
CONCLUSION: Kinetics of plasma DNA (ALU 115) is associated with response to neoadjuvant chemotherapy in patients with locally confined breast cancer. PMID: 23916787 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - August 2, 2013 Category: Cancer & Oncology Authors: Lehner J, Stötzer OJ, Fersching D, Nagel D, Holdenrieder S Tags: Clin Chim Acta Source Type: research

Antitumor Effect of 89Sr for Multiple Bone Metastases of Breast Cancer: Diagnosis by 18F-FDG PET/CT.
Abstract Sr is useful for the palliation of painful bone metastasis, but its antitumor activity as a monotherapy has not been shown by F-FDG PET. Here, we report a case of a 75-year-old woman with multiple bone metastases of breast cancer in which F-FDG PET demonstrated a significant reduction in uptake of F-FDG after administration of Sr. PMID: 23917785 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - August 2, 2013 Category: Cancer & Oncology Authors: Hama Y Tags: Clin Nucl Med Source Type: research

Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification.
CONCLUSIONS: In the absence of the gene amplification, HER2 protein overexpression may be explained by other mechanisms including polysomy 17. PMID: 23908451 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - August 1, 2013 Category: Cancer & Oncology Authors: Orsaria M, Khelifa S, Buza N, Kamath A, Hui P Tags: J Clin Pathol Source Type: research

Breast cancer prevention by antihormones and other drugs: where do we stand?
Abstract Breast cancer is the most common cancer in women worldwide. The selective estrogen-receptor (ER) modulators tamoxifen and raloxifene are approved by the Food and Drug Administration for the preventive therapy of breast cancer. Other drugs have shown promise but need further assessment. In the present review, we present an update of the chemoprevention of ER-positive breast cancer and discuss the potential role of metformin and aspirin, 2 drugs other than the specific "antihormones." PMID: 23915737 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - August 1, 2013 Category: Cancer & Oncology Authors: Lazzeroni M, Decensi A Tags: Hematol Oncol Clin North Am Source Type: research

Radiation Therapy for Duct Carcinoma in Situ: Who Needs Radiation Therapy, Who Doesn't?
Abstract Duct carcinoma in situ (DCIS) is a common but non-life-threatening breast cancer. Four large prospective randomized trials comparing radiation therapy (RT) with none after breast-conservation surgery have all concluded that the use of RT reduces the risk of a local recurrence (LR) in the ipsilateral breast by at least 50%. More information is needed to assess the role of antiestrogen therapy when RT is not given. When markers are validated to predict which patients will have an invasive LR versus another DCIS or no LR, it is hoped that the discussion with the patient will clarify the situation further. ...
Source: Clinical Breast Cancer - August 1, 2013 Category: Cancer & Oncology Authors: McCormick B Tags: Hematol Oncol Clin North Am Source Type: research

Management of the axilla.
Abstract The development and wide acceptance of sentinel lymph node biopsy (SLNB) has profoundly affected the management of breast cancer. SLNB has spared the additional morbidity of axillary lymph node dissection (ALND) without compromising diagnostic accuracy and prognostic information in patients with clinically node-negative early-stage breast cancer. It has become an invaluable tool to clinicians to guide decisions regarding adjuvant treatment. The management of breast cancer continues to advance to more minimally invasive approaches, and the role of ALND is likely to become less important in the future. ...
Source: Clinical Breast Cancer - August 1, 2013 Category: Cancer & Oncology Authors: Amersi F, Giuliano AE Tags: Hematol Oncol Clin North Am Source Type: research

Tailoring adjuvant treatments for the individual patient with luminal breast cancer.
Abstract Estrogen Receptor-positive/HER-2 negative breast cancers represent a heterogeneous group of tumors. Luminal A and B tumor subtypes can be identified through immunohistochemical assessment of estrogen and progesterone receptor, Ki-67 and HER-2 status. Patients with high levels of expression of steroid hormone receptors and low proliferation (Luminal A) are commonly cured with endocrine therapy alone. Patients with doubtful endocrine responsiveness or with high proliferation index (Luminal B/Her-negative) require the addition of chemotherapy to the best endocrine therapy. Controversies still exist on the id...
Source: Clinical Breast Cancer - August 1, 2013 Category: Cancer & Oncology Authors: Munzone E, Curigliano G, Colleoni M Tags: Hematol Oncol Clin North Am Source Type: research

Endocrine therapy for advanced/metastatic breast cancer.
Abstract First-line endocrine therapy by estrogen antagonism or suppression of estrogen achieves objective responses (ORs) and clinical benefit (CB) in around 30% and 50% of estrogen receptor-positive metastatic breast cancer patients, respectively. Aromatase inhibitors (AIs) are the most effective treatment in previously untreated postmenopausal women. Tamoxifen is an effective alternative. The optimal endocrine therapy on relapse remains uncertain. Tamoxifen and fulvestrant achieve CB in around 50% of patients and ORs of 10%. CB of exemestane after nonsteroidal AIs is 30% to 50% but ORs are rare. Targeted agents...
Source: Clinical Breast Cancer - August 1, 2013 Category: Cancer & Oncology Authors: Schiavon G, Smith IE Tags: Hematol Oncol Clin North Am Source Type: research

The management of early-stage and metastatic triple-negative breast cancer: a review.
Abstract Triple-negative breast cancer (TNBC), defined as lacking expression of the estrogen receptor, progesterone receptor, and HER2, comprises approximately 15% of incident breast cancers and is over-represented among those with metastatic disease. There are several biologically distinct subtypes within TNBC. Although the incidence of BRCA mutations across all subsets of breast cancer is low, BRCA mutations are more common among those with TNBC and may have therapeutic implications. The general principles guiding the use of chemotherapy and radiation therapy do not differ dramatically between early-stage TNBC a...
Source: Clinical Breast Cancer - August 1, 2013 Category: Cancer & Oncology Authors: Anders CK, Zagar TM, Carey LA Tags: Hematol Oncol Clin North Am Source Type: research

Treating the HER2 Pathway in Early and Advanced Breast Cancer.
Abstract ERBB2 gene amplification occurs in ∼20% of human breast cancers (BC) and is associated with an adverse clinical prognosis, indicating that it may be playing a critical role in disease pathogenesis. Therapeutic strategies targeting pathologic ERBB2 overexpression have revolutionized the diagnosis and treatment of BC. Indeed, humanized anti-ERBB2 antibodies, small molecule ERBB2 kinase inhibitors and ERBB2-targeting antibody-drug conjugates have proven safety and efficacy based upon evidence from randomized phase III clinical trials. Recent progress in targeting ERBB2 alteration will be reviewed, with f...
Source: Clinical Breast Cancer - August 1, 2013 Category: Cancer & Oncology Authors: Pegram MD Tags: Hematol Oncol Clin North Am Source Type: research

Neoadjuvant Therapy: What are the Lessons so far?
This article explains how diagnosis of a pathologic complete response (pCR) can avoid an unfavorable prognosis in patients with high-risk breast cancer; how the surrogacy of pCR for long-term survival remains questionable; how translational biomarker studies have not been helpful in identifying patients with a high chance of treatment benefit; assessment of the prognosis of patients without a pCR for identifying patients at high risk and which clinical trials will be available for these patients in the near future; and which patients might require less locoregional treatment. PMID: 23915744 [PubMed - in process] (Sour...
Source: Clinical Breast Cancer - August 1, 2013 Category: Cancer & Oncology Authors: von Minckwitz G Tags: Hematol Oncol Clin North Am Source Type: research

Challenges in the treatment of older breast cancer patients.
This article discusses how to evaluate older breast cancer patients and provides guidelines for optimal therapies in the adjuvant and metastatic treatment settings. PMID: 23915745 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - August 1, 2013 Category: Cancer & Oncology Authors: Williams GR, Jones E, Muss HB Tags: Hematol Oncol Clin North Am Source Type: research

Breast cancer survivorship issues.
Abstract Survivors of breast cancer are confronted with a plethora of cancer treatment-related long-term symptoms, the most common being fatigue, hot flashes, sexual dysfunction, arthralgias, neuropathy, and cognitive dysfunction. Survivors of breast cancer also face cancer treatment-related disease states, such as osteoporosis, cardiac dysfunction, obesity, infertility, and secondary cancers. Evidence-based recommendations for screening, prevention, and early intervention should be implemented to improve quality of life and decrease comorbidities in this population. PMID: 23915746 [PubMed - in process] (Sour...
Source: Clinical Breast Cancer - August 1, 2013 Category: Cancer & Oncology Authors: Stan D, Loprinzi CL, Ruddy KJ Tags: Hematol Oncol Clin North Am Source Type: research

What does breast cancer treatment cost and what is it worth?
Abstract The costs of breast cancer care are substantial and growing, and they extend across the spectrum of care. Medical therapies and hospitalizations account for a significant proportion of these costs. Cost-effectiveness analysis (CEA) is the preferred method for assessing the health benefits of medical interventions relative to their costs. Although many CEAs have been conducted for a wide range of breast cancer treatments, these analyses are not used routinely to guide coverage or utilization decisions in the United States. Currently, patients and providers may not consider costs when making most treatment ...
Source: Clinical Breast Cancer - August 1, 2013 Category: Cancer & Oncology Authors: Hassett MJ, Elkin EB Tags: Hematol Oncol Clin North Am Source Type: research

Breast cancer treatment in the era of individualized care.
PMID: 23915750 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - August 1, 2013 Category: Cancer & Oncology Authors: Burstein HJ Tags: Hematol Oncol Clin North Am Source Type: research

BRCA Genetic Testing: An RN's Personal Story.
Abstract T his story begins in early December 2011. I had received a diagnosis of ductal cancer in situ (DCIS), a noninvasive cancer staged at 0 in the ducts of my left breast (National Cancer Institute [NCI], 2009). The breast surgeon from whom I was obtaining a second opinion discussed lumpectomy versus mastectomy and radiation. Toward the end of the visit, the surgeon suggested that I have a laboratory workup for vitamin D levels. Vitamin D has been found in some studies to reduce breast cancer risk, and levels of vitamin D also have been found to be low in women with breast cancer (NCI, 2012b). I was directed ...
Source: Clinical Breast Cancer - August 1, 2013 Category: Cancer & Oncology Authors: Wasserman L Tags: Clin J Oncol Nurs Source Type: research

CYP2D6 Genotype Should Not Be Used to Determine Endocrine Therapy in Postmenopausal Breast Cancer Patients.
PMID: 23872830 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 24, 2013 Category: Cancer & Oncology Authors: Rae JM Tags: Clin Pharmacol Ther Source Type: research

Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance.
Abstract Human epidermal growth factor receptor 2-overexpressing (HER2+) breast cancer occurs in 20% to 25% of cases and is associated with poor prognosis. Trastuzumab (Herceptin; Genentech, South San Francisco, CA) is a monoclonal antibody targeting the HER2 extracellular domain that has been shown to significantly reduce relapse rates. However, some patients with HER2+ tumors do not respond to Herceptin, and 60% to 85% of patients with HER2+ metastatic breast cancer acquire resistance within a short time period. In this review, we discuss proposed mechanisms of action of trastuzumab and trastuzumab resistance an...
Source: Clinical Breast Cancer - July 9, 2013 Category: Cancer & Oncology Authors: Chung A, Cui X, Audeh W, Giuliano A Tags: Clin Breast Cancer Source Type: research

Correlation Between Nottingham Prognostic Index and Adjuvant! Online Prognostic Tools in Patients With Early-Stage Breast Cancer in Mid-Western Ireland.
CONCLUSIONS: This report underscores that these predicting tools were both underestimations consistent with the actual OS and highlights the importance of further work in validating these tools within our own population. PMID: 23829889 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 9, 2013 Category: Cancer & Oncology Authors: Quintyne KI, Woulfe B, Coffey JC, Gupta RK Tags: Clin Breast Cancer Source Type: research

Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer.
CONCLUSIONS: Significant antitumor activity was observed in all the arms. Weekly nab-P with bevacizumab appeared to have the highest therapeutic index. However, sensory neuropathy was treatment limiting, which suggests that a 3 weeks on and 1 week off schedule should be explored. PMID: 23829890 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 9, 2013 Category: Cancer & Oncology Authors: Seidman AD, Conlin AK, Bach A, Moynahan ME, Lake D, Forero A, Wright GS, Hackney MH, Clawson A, Norton L, Hudis CA Tags: Clin Breast Cancer Source Type: research

Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study.
CONCLUSION: Long-term benefit of trastuzumab-based therapy is associated with hormone receptor positivity and the absence of previous adjuvant trastuzumab. Nevertheless, clinicopathological features had a low predictive value for prolonged treatment duration. The validation of the current findings and the identification of molecular features associated the magnitude of trastuzumab benefit should be encouraged. PMID: 23829891 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 9, 2013 Category: Cancer & Oncology Authors: Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NU Tags: Clin Breast Cancer Source Type: research

Negligible Nuclear FOXP3 Expression in Breast Cancer Epithelial Cells Compared With FOXP3-Positive T Cells.
CONCLUSION: FOXP3 does most likely not play a significant role in breast cancer biology, because it is only scarcely expressed in a very small proportion of breast cancer samples. PMID: 23829892 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 9, 2013 Category: Cancer & Oncology Authors: Droeser RA, Obermann EC, Wolf AM, Wallner S, Wolf D, Tzankov A Tags: Clin Breast Cancer Source Type: research

Influence of body mass index on clinicopathological factors including estrogen receptor, progesterone receptor, and Ki67 expression levels in breast cancers.
CONCLUSION: Higher BMI might influence aggressive tumor characteristics among premenopausal patients, but its influence on ER, PR, and Ki67 expression levels seems to be limited. PMID: 23821234 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 3, 2013 Category: Cancer & Oncology Authors: Yanai A, Miyagawa Y, Murase K, Imamura M, Yagi T, Ichii S, Takatsuka Y, Ito T, Hirota S, Sasa M, Katagiri T, Miyoshi Y Tags: Int J Clin Oncol Source Type: research

Estrogen receptor beta 2 is associated with poor prognosis in estrogen receptor alpha-negative breast carcinoma.
Abstract PURPOSE: Our aim was to examine the prognostic significance of ERbeta1 and ERbeta2 expression in ERalpha-negative breast carcinomas. MATERIALS AND METHODS: We evaluated nuclear and cytoplasmic expression of ERbeta1 and ERbeta2 by immunohistochemistry in a group of 95 patients with long follow-up. ERbeta1 and ERbeta2 status was correlated with clinicopathological parameters and disease outcome. Univariate and multivariate analyses of ERbeta1 and ERbeta2 as independent markers of disease-free survival (DFS) were carried out using the Cox proportional hazards model. RESULTS: Nuclear ERbeta1 (nERbet...
Source: Clinical Breast Cancer - July 2, 2013 Category: Cancer & Oncology Authors: Chantzi NI, Tiniakos DG, Palaiologou M, Goutas N, Filippidis T, Vassilaros SD, Dhimolea E, Mitsiou DJ, Alexis MN Tags: J Cancer Res Clin Oncol Source Type: research

Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy.
CONCLUSIONROR provides more prognostic information in endocrine-treated patients with ER-positive, node-negative disease than RS, with better differentiation of intermediate- and higher-risk groups. PMID: 23816962 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 1, 2013 Category: Cancer & Oncology Authors: Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, Ferree S, Storhoff J, Schaper C, Cuzick J Tags: J Clin Oncol Source Type: research

Breast cancer in older patients: national cancer registry data.
CONCLUSION: This short communication reports on the increasing registration of breast cancer in the older age group which will present a number of challenges for the future. PMID: 23758449 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 16, 2013 Category: Cancer & Oncology Authors: Sinha R, Coyle C, Ring A Tags: Int J Clin Pract Source Type: research

Academic and Nonacademic Laboratories Perform Equally on CIQC Immunohistochemistry Proficiency Testing.
Abstract Objectives: To test whether academic centers (ACs) are more successful than nonacademic centers (NACs) in immunohistochemistry (IHC) external quality assessment challenges in the Canadian Immunohistochemistry Quality Control (CIQC) program. Methods: Results of 9 CIQC challenges for breast cancer marker (BM) and various non-breast cancer marker (NBM) tests were examined. Success rates were compared between AC/NAC laboratories and those located in small or large cities. Performance was also correlated with annual IHC case volumes. Results: There was no statistically significant difference in performance in ...
Source: Clinical Breast Cancer - June 16, 2013 Category: Cancer & Oncology Authors: Chen ZW, Neufeld H, Copete MA, Garratt J, Gilks CB, Torlakovic EE Tags: Am J Clin Pathol Source Type: research

Breast cancer in ghanaian women: what has changed?
Abstract Objectives: To evaluate breast cancer in Ghanaian women and to compare these findings with those of previous studies by using histopathologic data. Methods: A review of all breast cancer specimens from January 2005 through December 2009 in our institution was conducted. Results: Of 4,109 female breast specimens reviewed, 1,342 (32.7%) were malignant. Mean (SD) patient age was 50.3 (13.3) years, and mean size of the primary tumors was 4.5 cm. Eighteen (1.3%) specimens were malignant phyllodes tumors. Significant positive associations were found between size of the primary tumor and histologic type (P = .01...
Source: Clinical Breast Cancer - June 16, 2013 Category: Cancer & Oncology Authors: Edmund DM, Naaeder SB, Tettey Y, Gyasi RK Tags: Am J Clin Pathol Source Type: research

Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management.
CONCLUSION: Despite the fact that omeprazole is one of the most widely prescribed drugs internationally, clinical professionals should enhance clinical risk management on adverse DDIs associated with omeprazole and ensure safe combination use of omeprazole by rationally prescribing alternatives, checking the appropriateness of physician orders before dispensing, and performing therapeutic drug monitoring. PMID: 23745048 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 12, 2013 Category: Cancer & Oncology Authors: Li W, Zeng S, Yu LS, Zhou Q Tags: Ther Clin Risk Manag Source Type: research

Over-sulfated glycosaminoglycans are alternative selectin ligands: insights into molecular interactions and possible role in breast cancer metastasis.
We report herein that cancer-associated GAGs are differentially recognized by selectins according to their density of sulfation and the pH conditions of the binding. We also show that these parameters regulate platelets-cancer cells heterotypic aggregation, supporting the idea that GAGs may have pro-metastatic function. Combining our experimental results with in depth analyses of molecular dockings, we propose a model of GAG/selectin interactions robust enough to recapitulate the differential binding of selectins to GAGs, the competition between GAGs and sLe(x) for selectin binding and the effect of sub-physiological pH on...
Source: Clinical Breast Cancer - June 6, 2013 Category: Cancer & Oncology Authors: Martinez P, Vergoten G, Colomb F, Bobowski M, Steenackers A, Carpentier M, Allain F, Delannoy P, Julien S Tags: Clin Exp Metastasis Source Type: research

Orally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patients.
CONCLUSIONS: This exploratory study showed that GBL levels increased, VEGF levels decreased, and CEC levels were suppressed during S-1 administration. S-1 appears to have anti-angiogenic activity. PMID: 23739924 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 6, 2013 Category: Cancer & Oncology Authors: Tsuji W, Ishiguro H, Tanaka S, Takeuchi M, Ueno T, Toi M Tags: Int J Clin Oncol Source Type: research

Role of XRCC3, XRCC1 and XPD single-nucleotide polymorphisms in survival outcomes following adjuvant chemotherapy in early stage breast cancer patients.
nto R Abstract INTRODUCTION: Anthracyclines have various mechanisms of action that in the end lead to DNA double-strand breaks. Single-nucleotide polymorphisms (SNPs) in DNA repair genes may alter the protein function, affecting DNA repair proficiency and, therefore, the efficiency of DNA damaging chemotherapy. We have analysed whether SNPs in DNA repair genes (XRCC1, XRCC3 and XPD) could be useful to predict the response to anthracyclines in patients with early-stage breast cancer (EBC). METHODS: Peripheral blood samples from 150 patients with EBC were used for genotyping XRCC3Thr241Met, XRCC1Arg399Gln and XPDLys...
Source: Clinical Breast Cancer - June 6, 2013 Category: Cancer & Oncology Authors: Castro E, Olmos D, Garcia A, Cruz JJ, González-Sarmiento R Tags: Clin Transl Oncol Source Type: research

Targeting treatment resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.
CONCLUSIONS: AD-01 has dual anti-angiogenic and anti-BCSC activity which will be advantageous as this agent enters clinical trial. PMID: 23741069 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 5, 2013 Category: Cancer & Oncology Authors: McClements L, Yakkundi A, Papaspyropoulos A, Harrison H, Ablett MP, Jithesh PV, McKeen HD, Bennett R, Donley C, Kissenpfennig A, McIntosh S, McCarthy HO, O'Neill E, Clarke RB, Robson T Tags: Clin Cancer Res Source Type: research

Breast cancer: Timing of sentinel-node biopsy.
PMID: 23736645 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 4, 2013 Category: Cancer & Oncology Authors: Marchesi V Tags: Nat Rev Clin Oncol Source Type: research

Potential survival benefit with lumpectomy for patients with early-stage breast cancer.
PMID: 23733540 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 3, 2013 Category: Cancer & Oncology Authors: Barton MK Tags: CA Cancer J Clin Source Type: research

Pregnancy During or After Breast Cancer Diagnosis: What Do We Know and What Do We Need to Know?
Abstract PMID: 23733755 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 3, 2013 Category: Cancer & Oncology Authors: Theriault RL, Litton JK Tags: J Clin Oncol Source Type: research

Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy.
CONCLUSIONThere was no evidence that ALC affected CIPN at 12 weeks; however, ALC significantly increased CIPN by 24 weeks. This is the first study to our knowledge showing that a nutritional supplement increased CIPN. Patients should be discouraged from using supplements without proven efficacy. PMID: 23733756 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 3, 2013 Category: Cancer & Oncology Authors: Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS Tags: J Clin Oncol Source Type: research

Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer.
CONCLUSIONWhile the primary study end point was not met, adding cetuximab to cisplatin doubled the ORR and appeared to prolong PFS and OS, warranting further investigation in mTNBC. PMID: 23733761 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 3, 2013 Category: Cancer & Oncology Authors: Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pêgo A, Chan A, Goeminne JC, Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, Zubel A, Groos J, Melezínková H, Awada A Tags: J Clin Oncol Source Type: research

Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study.
CONCLUSIONFor patients with high-risk node-negative BC, the adjuvant FAC-wP regimen was associated with a small but significant improvement in DFS compared with FAC therapy, in addition to manageable toxicity, especially regarding long-term cardiac effects. PMID: 23733779 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 3, 2013 Category: Cancer & Oncology Authors: Martín M, Ruiz A, Borrego MR, Barnadas A, González S, Calvo L, Vila MM, Antón A, Rodríguez-Lescure A, Seguí-Palmer MA, Muñoz-Mateu M, Ribugent JD, López-Vega JM, Jara C, Espinosa E, Fernández CM, Andrés R, Ribelles N, Plazaola A, Sánchez-Rovira Tags: J Clin Oncol Source Type: research

1,25-dihydroxyvitamin D in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.
1,25-dihydroxyvitamin D in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Expert Rev Clin Immunol. 2013 Jun;9(6):517-33 Authors: Trowbridge R, Kizer RT, Mittal SK, Agrawal DK Abstract The incidence of reflux-related esophageal disease - Barrett's esophagus and esophageal adenocarcinoma - is rising, and the prognosis remains poor. Evidence exists that 1,25-dihydroxyvitamin D may augment the course of colon, breast and prostate cancer but little knowledge exists regarding its impact on disease of the esophagus. Important immune cells involved in reflux-related esophageal dis...
Source: Clinical Breast Cancer - June 1, 2013 Category: Cancer & Oncology Authors: Trowbridge R, Kizer RT, Mittal SK, Agrawal DK Tags: Expert Rev Clin Immunol Source Type: research

Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in Monitoring the Response of Breast Cancer to Neoadjuvant Chemotherapy: A Meta-Analysis.
CONCLUSIONS: Analysis of the findings suggests that FDG-PET has moderately high sensitivity and specificity in early detection of responders from nonresponders, and can be applied in the evaluation of breast cancer response to neoadjuvant chemotherapy in patients with breast cancer. PMID: 23714689 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 25, 2013 Category: Cancer & Oncology Authors: Mghanga FP, Lan X, Bakari KH, Li C, Zhang Y Tags: Clin Breast Cancer Source Type: research

Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials.
Rugo H, Yee D, Esserman L Abstract New approaches to drug development are critically needed to lessen the time, cost, and resources necessary to identify and optimize active agents. Strategies to accelerate drug development include testing drugs earlier in the disease process, such as the neoadjuvant setting. The U.S. Food and Drug Administration (FDA) has issued guidance designed to accelerate drug approval through the use of neoadjuvant studies in which the surrogate short-term endpoint, pathologic response, can be used to identify active agents and shorten the time to approval of both efficacious drugs and biom...
Source: Clinical Breast Cancer - May 16, 2013 Category: Cancer & Oncology Authors: Demichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Tags: Clin Cancer Res Source Type: research

Predictive Biomarkers for Bevacizumab: Are We There Yet?
Abstract Therapy targeting VEGF has become the standard of care in several solid malignancies. Early investigations attempting to identify predictive markers for the efficacy of therapy failed to identify any predictive markers that could help oncologists decide who should-and, more importantly, who should not-receive VEGF-targeted therapies. However, interest has been renewed in predictive biomarkers for VEGF-targeted therapies, especially in light of the fact that the U.S. Food and Drug Administration withdrew approval for use of bevacizumab, an antibody to VEGF, in patients with metastatic breast cancer. In a r...
Source: Clinical Breast Cancer - May 16, 2013 Category: Cancer & Oncology Authors: Maru D, Venook AP, Ellis LM Tags: Clin Cancer Res Source Type: research

Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2-Negative Advanced Breast Cancer That Progressed during or after Bevacizumab.
CONCLUSION: The addition of sorafenib to gemcitabine/capecitabine provided a clinically small but statistically significant PFS benefit in HER2-negative advanced breast cancer patients whose disease progressed during/after bevacizumab. Combination treatment was associated with manageable toxicities but frequently required dose reductions. Clin Cancer Res; 19(10); 2745-54. ©2013 AACR. PMID: 23444220 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 15, 2013 Category: Cancer & Oncology Authors: Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani V, Stepanski EJ, Rugo HS, Wang W, Bell-McGuinn K, Kirshner JJ, Eisenberg P, Emanuelson R, Keaton M, Levine E, Medgyesy DC, Qamar R, Starr A, Ro SK, Lokker NA, Hudis CA Tags: Clin Cancer Res Source Type: research

Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance.
Abstract PURPOSE: Estrogen withdrawal by treatment with aromatase inhibitors is the most effective form of endocrine therapy for postmenopausal estrogen receptor-positive (ER+) breast cancer. However, response to therapy varies markedly and understanding of the precise molecular effects of aromatase inhibitors and causes of resistance is limited. We aimed to identify in clinical breast cancer those genes and pathways most associated with resistance to aromatase inhibitors by examining the global transcriptional effects of AI treatment. EXPERIMENTAL DESIGN: Baseline and 2-week posttreatment biopsies were obtai...
Source: Clinical Breast Cancer - May 15, 2013 Category: Cancer & Oncology Authors: Dunbier AK, Ghazoui Z, Anderson H, Salter J, Nerurkar A, Osin P, A'hern R, Miller WR, Smith IE, Dowsett M Tags: Clin Cancer Res Source Type: research

Neoadjuvant Chemotherapy with or without Zoledronic Acid in Early Breast Cancer--A Randomized Biomarker Pilot Study.
CONCLUSIONS: In this pilot study, short-term changes in biomarkers suggest potentially relevant interactions between tumor biology, chemotherapy, modification of the bone microenvironment, and the endocrine status of the host. Larger studies with more frequent dosing of zoledronic acid are needed to assess these complex interactions more thoroughly. Clin Cancer Res; 19(10); 2755-65. ©2013 AACR. PMID: 23515409 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 15, 2013 Category: Cancer & Oncology Authors: Winter MC, Wilson C, Syddall SP, Cross SS, Evans A, Ingram CE, Jolley IJ, Hatton MQ, Freeman JV, Mori S, Holen I, Coleman RE Tags: Clin Cancer Res Source Type: research